Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062491 · ClinicalTrials.gov registry record · Phase 2
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
A Phase 2 study of Melanoma and Neoplasm, sponsored by BioNumerik Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00062491 is a Phase 2 study of Melanoma and Neoplasm that has completed, run by BioNumerik Pharmaceuticals. The registered enrollment target is 46 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00062491, a Phase 2 study of Melanoma and Neoplasm, has completed, sponsored by BioNumerik Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
Interventions
- DRUG Karenitecin (BNP1350)
Study Locations (1)
Florida
- For Information call 210-614-1701 for a site near you - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2002-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062491
The ClinicalTrials.gov registry entry for NCT00062491 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The listed sponsor is BioNumerik Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Karenitecin (BNP1350) is the first listed.
NCT00062491 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00062491 about?
NCT00062491 is a clinical study titled "Study of Karenitecin (BNP1350) to Treat Malignant Melanoma". The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
What is the current status of trial NCT00062491?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2002-05. Estimated completion is 2005-11.
What conditions does trial NCT00062491 study?
This clinical trial studies the following conditions: Melanoma, Neoplasm.
What interventions are being tested in trial NCT00062491?
The interventions under investigation include: Karenitecin (BNP1350) (DRUG).
Who is sponsoring clinical trial NCT00062491?
This trial is sponsored by BioNumerik Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00062491 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.